SCHOTT Pharma AG & Co. KGaA/€1SXP
1D1W1MYTD1Y5YMAX
Capital at risk
About SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA specializes in the design and manufacture of drug containment and delivery solutions for injectable medications, including prefillable glass and polymer syringes, cartridges, vials, and ampoules. Established as a standalone entity in August 2022 following its separation from SCHOTT AG, the company is headquartered in Mainz, Germany, and operates 16 manufacturing sites across Europe, North and South America, and Asia. With a portfolio of over 1,000 patents and a dedicated R&D center in Switzerland, SCHOTT Pharma focuses on developing innovative solutions to meet the evolving needs of the pharmaceutical industry. The company serves over 1,800 customers, including the top 30 pharmaceutical manufacturers for injectable drugs, and reported revenues of €821 million in the fiscal year 2022. SCHOTT Pharma is committed to sustainable development, aiming to achieve climate neutrality by 2030.
- Ticker
- €1SXP
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 5,002
- Headquarters
- Mainz, Germany
- Website
- www.schott-pharma.com
1SXP Metrics
BasicAdvanced
€3.4B
25.03
€0.90
0.98
€0.18
0.80%
Price and volume
Market cap
€3.4B
Beta
0.98
52-week high
€23.70
52-week low
€12.54
Average daily volume
73K
Dividend rate
€0.18
Financial strength
Current ratio
1.606
Quick ratio
0.737
Long term debt to equity
0.077
Total debt to equity
0.309
Dividend payout ratio (TTM)
19.90%
Interest coverage (TTM)
10.08%
Profitability
EBITDA (TTM)
249.297
Gross margin (TTM)
31.17%
Net profit margin (TTM)
13.40%
Operating margin (TTM)
16.45%
Effective tax rate (TTM)
21.85%
Revenue per employee (TTM)
€200,000
Management effectiveness
Return on assets (TTM)
6.49%
Return on equity (TTM)
14.67%
Valuation
Price to earnings (TTM)
25.032
Price to revenue (TTM)
3.345
Price to book
3.39
Price to tangible book (TTM)
3.5
Price to free cash flow (TTM)
61.911
Free cash flow yield (TTM)
1.62%
Free cash flow per share (TTM)
0.364
Dividend yield (TTM)
0.80%
Forward dividend yield
0.80%
Growth
Revenue change (TTM)
4.15%
Earnings per share change (TTM)
-7.25%
3-year revenue growth (CAGR)
5.21%
3-year earnings per share growth (CAGR)
-1.78%
3-year dividend per share growth (CAGR)
12.92%
Bulls say / Bears say
Q3 momentum exceeded the earlier trajectory: constant-currency revenue increased 8.3%, prompting SCHOTT Pharma to raise full-year 2026 guidance to 5–6% revenue growth and a 27–28% EBITDA margin. (SCHOTT Pharma)
The company is gaining exposure to attractive injectable-drug trends: demand for prefillable glass syringes for GLP-1 medicines remained strong, while polymer-syringe demand outside mRNA applications improved. (SCHOTT Pharma)
Cash generation strengthened substantially, with nine-month free cash flow rising 49% to €58.9 million; management says the improved financial position and financing optimization provide flexibility to pursue growth opportunities. (SCHOTT Pharma)
DDS remains a weak spot: nine-month revenue fell 1.7% at constant currencies, primarily because lower polymer-syringe demand tied to declining mRNA vaccinations outweighed growth in other applications and GLP-1-related prefillable glass syringes. (SCHOTT Pharma)
Profitability is under pressure despite sales growth: nine-month EBITDA declined to €205.3 million and the margin fell to 26.7% from 28.9% a year earlier. (SCHOTT Pharma)
DDS execution risks remain material, with lower polymer-syringe capacity utilization, a customer-specific glass-syringe impairment, and additional infrastructure and production-optimization costs reducing segment EBITDA by 16.3% in the first nine months. (SCHOTT Pharma)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.
Upcoming events
No upcoming events
Funds containing 1SXP
AllEURGBPUSD
Fund name | Fund size | €1SXP weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.06% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.06% |
WisdomTree Global Quality Dividend Growth£GGRG | £1.9B | 0.02% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.